EPISODE · Dec 17, 2021 · 14 MIN
MPR Weekly Dose 102 - COVID-19 vaccine contraindication; Final results for COVID-19 antiviral; Entadfi approved; CAR T-cell REMS change; New approval for psoriatic arthritis
from MPR Weekly Dose
Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis.
Embed this episode
Ready to play
MPR Weekly Dose 102 - COVID-19 vaccine contraindication; Final results for COVID-19 antiviral; Entadfi approved; CAR T-cell REMS change; New approval for psoriatic arthritis
0:00
14:21
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 14 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on December 17, 2021.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!